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Advanced cervical cancer is the fifth most common cancer world-
wide and is the second major cause of death in women (Parkin
et al, 1988). Studies on the use of cisplatin have shown that
squamous cell carcinoma of the uterine cervix is sensitive to
chemotherapy (Thigpen et al, 1981; Alberts et al, 1987). Various
cisplatin-based regimens have been associated with high responses
in patients with advanced and recurrent cervical cancers
(Lahousen et al, 1987; Omura et al, 1992; Thigpen et al, 1995).
However, only a few well-designed randomized studies have been
carried out, and chemotherapy in patients with refractory cervical
cancer usually results in excessive toxicity and a short duration of
response with no survival advantage. In recent years, cisplatin-
containing chemotherapy has been used as neoadjuvant
chemotherapy (NAC) to treat patients with International
Federation of Gynecology and Obstetrics (FIGO) stage IIb, III, or
IV diseases as well as stage Ib or IIa disease with a bulky mass.
NAC has been reported as useful in the control of local or regional
disease, and is useful in controlling remote metastasis (Benedetti-
Panici et al, 1991; Souhami et al, 1991; Vermorken, 1993;
Scarabelli et al, 1995; Sundfor et al, 1996; Sugiyama et al, 1998a).
Recently, NAC followed by radical surgery has been proposed to
improve the survival rate of patients with locally advanced
cervical cancer (Benedetti-Panici et al, 1991; Scarabelli et al,
1995; Sugiyama et al, 1998a). Because the optimal NAC regimen
has only recently been established, we need to develop a new
combination chemotherapy regimen to achieve clinical benefits in
the treatment of locally advanced cervical cancer.
Irinotecan hydrochloride (CPT-11) is a semisynthetic derivative
of camptothecin, a plant alkaloid obtained from Camptotheca
acuminata (Wall et al, 1996), which is capable of potent anti-
tumour activity. The anti-tumour effects of CPT-11 are related to
the inhibition of DNA topoisomerase I (Kunimoto et al, 1987;
Hsiang et al, 1989), a novel mechanism among other anti-tumour
agents. CPT-11 expresses a potent activity against various experi-
mental tumour models (Matsuzaki et al, 1988) and shows slow
cross-resistance to other anti-tumour agents (Tsuruo et al, 1988). It
has also been found in some clinical trials to be clinically active
against various cancers including cervical cancer (Takeuchi et al,
1991; Verschraegen et al, 1997; Irvin et al, 1998). Moreover, the
combination of CPT-11 and cisplatin, which has shown a marked
synergism experimentally (Itoh et al, 1991; Kano et al, 1992;
Minagawa et al, 1994), has been reported to be effective, with
acceptable toxicity, against advanced or recurrent cervical cancer
(Sugiyama et al, 1995; Sugiyama et al, 1998b). In a phase I study
of a combination of CPT-11 with cisplatin, in which cisplatin was
administered at the recommended dose of 60 mg m—2 on day 1,
CPT-11 was administered at doses of 60 mg m—2 on days 1, 8 and
15 (Sugiyama et al, 1995).
We conducted a phase II study of CPT-11 administered in
combination with cisplatin to patients with locally advanced
cervical cancer. The objectives of this study were to determine the
efficacy and safety of the combination as a neoadjuvant
chemotherapy.
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Summary To evaluate the response rate and toxicity of the combination of irinotecan (CPT-11) and cisplatin in a neoadjuvant setting, a phase
II study was conducted regarding the regimen of this combination in patients with locally advanced cervical cancer. Eligibility included patients
with previously untreated stage Ib2, IIb, or IIIb squamous cell carcinoma with good performance status. CPT-11 (60 mg m–2) was administered
intravenously on days 1, 8 and 15, followed by cisplatin (60 mg m–2) given intravenously on day 1. Treatment was repeated every 4 weeks for
a total of two or three cycles. Among 23 eligible patients (median age: 59 years), three showed complete response (13%), 15 showed partial
response (65%), for an overall response rate of 78% (95% confidence interval 58–90%). Stable disease was observed in four cases (17%)
and progressive disease in one (4%). The median time to failure and median survival time have not yet been reached. Of the 52 treatment
cycles administered, diarrhoea and grade 3 or 4 neutropenia were observed in 10% and 75% respectively. There were no therapy-related
deaths. The combination of CPT-11 with cisplatin is a promising regimen for neoadjuvant chemotherapy in locally advanced cervical cancer.
The toxicities of this regimen are well tolerated.
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Patient selection
Previously untreated patients with stage Ib, IIb, or IIIb squamous
cell carcinoma of the cervix were enrolled. Eligibility criteria were
as follows: age † 75 years, World Health Organization (WHO)
Performance Status (PS) of † 2, adequate bone marrow reserve
(leukocyte count: ‡ 4 ´ 103 ml—1, platelet count: ‡ 100 ´ 103 ml—1),
and adequate renal and hepatic function (serum creatinine: <1.5
mg dl—1, creatinine clearance: ‡ 50 ml min—1, BUN: < 25 mg dl—1,
AST and ALT: † twice the upper normal limit, and serum total
bilirubin: < 1.5 mg dl—1). All patients gave their written informed
consent for participation.
Treatment design
We designed the dose and treatment schedule of cisplatin and
CPT-11 on the basis of our phase I study in patients with recurrent
or advanced cervical cancer (Sugiyama et al, 1995). An intra-
venous (i.v.) infusion of over 60 min of CPT-11 60 mg m—2 was
given on days 1, 8 and 15. On completion of CPT-11 infusion on
day 1, cisplatin at 60 mg m—2 was administered i.v. for over 90 min.
Before and after cisplatin administration, patients received i.v.
hydration with 1500—2000 ml 0.9% normal saline or 5%
dextrose. A 5-HT3 serotonin receptor antagonist was administered
according to the attending physician￿s judgment. Granulocyte
colony-stimulating factor (G-CSF) was administered if grade 3
neutropenia with fever (‡ 38.0°C) or grade 4 neutropenia devel-
oped. This treatment schedule was repeated every 4 weeks for two
or three cycles. Following chemotherapy, radical surgery was
performed in all patients with stages Ib2 and IIb disease who were
younger than 70. With regard to IIIb disease, patients underwent
radical surgery only if they responded to chemotherapy, and if
cancer-free space between the tumour and the pelvic wall was
recognized on rectal examination at the completion of NAC.
Patients with stage IIIb disease who did not respond to
chemotherapy underwent radiotherapy.
The dose levels and treatment schedule were modified to avoid
severe side-effects. CPT-11 was not given on days 8 and/or 15 if the
patient￿s leukocyte or platelet counts were less than 3.0 ´ 103 ml—1 or
less than 75 ´103 ml—1 respectively. It was also withheld if the patient
developed diarrhoea of grade 2 or worse according to the Eastern
Cooperative Oncology Group (ECOG) scale (Oken et al, 1982).
Before the next cycle was started, a leukocyte count
‡ 3.0  ´ 103 ml—1, and platelet count ‡ 100 ´ 103 ml—1, with no diar-
rhoea observed, and liver and renal function according to the eligi-
bility criteria had to be satisfied. Additionally, if ‡ grade 3 diarrhoea
during any cycle was observed, the CPT-11 dose in the next
cycle was reduced to 50 mg m—2. If serum creatinine level showed
1.5 times the upper normal limit, the cisplatin dose was reduced
to 50 mg m—2.
The trial was approved by the Institutional Review Board of the
Clinical Oncology Program at each hospital.
Response evaluation
Cervical tumour measurements using magnetic resonance imaging
(MRI) were obtained at the completion of every treatment cycle.
Measurement of response was based on the product of the two
largest perpendicular diameters. Criteria for tumour response were
as follows: complete response (CR) was defined as the complete
disappearance of all known disease for a minimum of 4 weeks,
with no development of new disease. Partial response (PR) was
defined as a ‡ 50% reduction of the sum of products of measurable
lesions for a minimum of 4 weeks with no development of new
lesions. Progressive disease (PD) was defined as a ‡ 25% increase
in the sum of the products of all indicator lesions, or reappearance
of any lesion that had disappeared, or appearance of any new
lesion. Stable disease (SD) was defined by any situation that did
not qualify as response or progression. Serum squamous cell
carcinoma-associated antigen (SCC) level was measured using
a commercially available kit (Abbott Laboratories, Diagnostic
Division, Silic 203, France) at the completion of every treatment
cycle.
Toxicity evaluation was based on WHO criteria (WHO offset
publication, 1979), except for diarrhoea, which was based on
Eastern Cooperative Oncology Group (ECOG) criteria (Oken et
al, 1982). Complete blood cell counts were performed at least
twice weekly. Serum chemistries and liver function tests were
obtained before every treatment cycle.
RESULTS
Between May 1996 and April 1998, 23 patients with locally
advanced squamous cell cervical cancer who had no prior therapy
were enrolled from the three cooperating institutions. The
patients￿ median age was 59 years (range 23—75 years). Nineteen
patients (83%) had a PS of 0, and four patients (17%) a PS of 1.
Two patients (9%) had stage Ib2 disease, eight (35%) had stage IIb
disease with bulky mass (‡ 4 cm) and 13 patients (57%) had stage
IIIb disease. All patients are assessable for response and toxicity.
Seventeen patients (74%) received two cycles of therapy, and the
remaining six patients received three cycles of therapy (Table 1).
Response to therapy
There were three CRs (13%) and 15 PRs (65%), with an overall
response rate of 78% (95% confidence interval (CI) 58—90%). SD
was observed in four patients (17%), while PD was recorded in
only one (4%) patient. Table 2 lists results according to FIGO
stage. Twenty patients (87%) had positive serum SCC levels
(‡ 1.5 ng ml—1) before treatment. SCC level fell to negative in all
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Table 1 Patient characteristics
Characteristic No. of patients %












21 7 7 4
36 2 6
aInternational Federation of Gynecology and Obstetrics (FIGO).three patients with CR. Among 13 patients with PR, the level fell
to negative in ten patients (77%) and decreased in three patients
(23%). Among three patients with SD, the level fell to negative in
one patient and decreased in the remaining two patients. However,
the level was elevated in one patient with PD.
Among ten cases of Ib and IIb stage, radical surgery was
performed after NAC in nine cases (younger than 70) with the
patient￿s consent, and radiotherapy was performed for the
remaining one patient who was older than 70. In ten patients with
stage IIIb disease who responded to NAC, their symptomatic stage
improved and radical surgery was considered to be possible, so
radical surgery was performed for five patients. Radiotherapy was
performed in the three patients whose informed consent for opera-
tion was not obtained and in the remaining two patients of
advanced age (> 70 years). Radiotherapy was also performed in
three patients of SD or PD to NAC.
Toxicity
The major toxicity was neutropenia, of which grade 3 or 4 severity
developed in 29 treatment cycles (56%) or ten treatment cycles
(19%) of a total of 52 treatment cycles respectively. Grade 2
infection occurred in two cycles (4%). G-CSF was administered
for 2—6 days during 11 (21%) of the 52 treatment cycles.
Thrombocytopenia was less common, and grade 3 or 4 thrombo-
cytopenia was not recorded. Grade 3 anaemia occurred in 14 of a
total of 52 cycles; grade 4 anaemia was not observed. Two patients
(9%) required a total 5 U of packed RBCs because of consecutive
radical surgeries.
The second major toxicity was diarrhoea, which developed in
31 cycles (60%) of a total of 52 cycles, though grade 3 or 4
diarrhoea was observed in just five cycles (10%). Diarrhoea
diminished with administration of loperamide hydrochloride
and/or i.v. drop infusion of electrolyte for 2—3 days. Nausea and
vomiting was also a common expression of non-haematologic
toxicity, and grade 2 severity or above was recorded in 30 cycles
(58%). Alopecia was observed in 20 patients (91%), in which
grade 2 severity was 50%. Other adverse effects such as neurolog-
ical toxicity, dermatitis, stomatitis, or allergic reactions were not
observed (Table 3).
While CPT-11 administration was omitted on days 8 or 15 in 16
(31%) of 52 treatment cycles because of the presence of ‡ grade 2
diarrhoea and/or neutropenia (leukopenia), a dose reduction was
required in only 3 cycles (6%), and a > 1 week treatment delay was
observed in only 2 cycles (4%). There were no treatment-related
deaths.
DISCUSSION
In addition to cisplatin, bleomycin, 5-fluorouracil, mitomycin C,
ifosfamide, vincristine, adriamycin and CPT-11 are also active
against uterine cervical cancer (Thigpen et al, 1981, 1995; Alberts
et al, 1987; Lahousen et al, 1987; Takeuchi et al, 1991; Omura et
al, 1992; Verschraegen et al, 1997; Irvin et al, 1998). In a previous
phase II study of the effect of CPT-11 alone on recurrent cervical
cancer in Japan, CPT-11 was given at a dose of 100 mg m—2 four
times with 1-week intervals and at a dose of 150 mg m—2 three
times with 2-week intervals (Takeuchi et al, 1991). The response
rate was 23.6%, and there was no significant difference between
the two schedules. The major toxicities were leukopenia and diar-
rhoea in both schedules. In a phase II study of patients who had
previously undergone chemotherapy in the USA, CPT-11 was
given at a dose of 125 mg m—2 four times with 1-week intervals,
and the response rate, 21%, was similar to the results in Japan
(Verschraegen et al, 1997). It was thus recognized that CPT-11 is
effective against cervical cancer.
There is reportedly no cross-resistance but a synergistic effect in
vitro between CPT-11 and cisplatin (Tsuruo et al, 1988; Kano et al,
1992; Minagawa et al, 1994). In a phase I study of a combination
of CPT-11 with cisplatin, in which cisplatin was administered at
the recommended dose of 60 mg m—2 on day 1, CPT-11 was admin-
istered at doses of 60 mg m—2 on days 1, 8 and 15 (Sugiyama et al,
1995). Recently, a phase II study of the combination of CPT-11
and cisplatin based on the results of the phase I study in patients
with advanced and recurrent cervical cancer was completed and
the effectiveness and safety of this regimen have been described
(Sugiyama et al, 1998b). We conducted the present study in a
neoadjuvant setting at the same time. Neutropenia was the dose-
limiting toxicity but was reversed by treatment with G-CSF or by
omitting CPT-11 administration on day 8 or 15. Thrombo-
cytopenia was infrequent and less severe. Diarrhoea developed in
60% of the cycles, but it was mild and was controlled with the use
of antidiarrhoeal agents, such as loperamide. Prophylactic and/or
therapeutic administration of a 5-HT3 serotonin receptor antago-
nist reduced the severity of nausea and vomiting.
Although high response rates induced by NAC have been
reported by many investigators, it is difficult to compare the
results of these reports because of the wide variation in the
patients￿ characteristics. In general, the response rate has been
reported to be around 70% for NAC with a cisplatin-based
CPT-11/cisplatin in cervical cancer 97
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Table 2 Results according to stage
Response
Stagea No. of patients CR PR SD PD
Ib2 2 0 1 1 0
IIb 8 1 6 1 0
IIIb 13 2 8 2 1
Total (%) 23 3 (13) 15 (65) 4 (17) 1 (4)
CR, complete response; PR, partial response; SD, stable disease; PD,
progressive disease. aStage, International Federation of Gynecology and
Obstetrics (FIGO).
Table 3 Toxicitya (per treatment cycles, n = 52)
Grade 1 Grade 2 Grade 3 Grade 4
No. % No. % No. % No. %
Haematological
Anaemia 13 25 16 31 14 27 0 0
Leukopenia 14 27 23 44 10 19 4 8
Neutropenia 1 2 12 23 29 56 10 19
Thrombocytopenia 3 6 2 4 0 0 0 0
Gastrointestinal
Nausea/vomiting 14 27 22 42 7 13 1 2
Liver toxicity 3 6 1 2 0 0 0 0
Diarrhoea 13 25 13 25 2 4 3 6
Renal toxicity 8 15 2 4 0 0 0 0
Alopeciab 15 65 6 26 – – – –
aWorld Health Organization (WHO) criteria. bPer patient (n = 23). regimen (Benedetti-Panici et al, 1991; Souhami et al, 1991;
Vermorken, 1993; Scarabelli et al, 1995; Sundfor et al, 1996;
Sugiyama et al, 1998a). In this study, we observed a response rate
of 78%. These results can be favourably compared with the values
described, and toxicity could be controlled.
In conclusion, combination therapy with CPT-11 and cisplatin
appeared to be highly active and improve the operability rate
against previously untreated uterine cervical cancer over short
periods of time. Its toxicity is acceptable, and the regimen is worth
consideration in respect to its effect of extending the survival time
in cases undergoing NAC followed by radical surgery for progres-
sive stage cervical cancers.
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